Includes a new ergonomic probe to operate in ideal MHz range to view all layers of skin
| Source: Sensus Healthcare, Inc.
BOCA RATON, Fla, Aug. 09, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces an upgrade to its full-featured SRT-100 Vision™ system with new state-of-the-art solid state High-Frequency Ultrasound. The system includes a new ergonomically designed probe for superior handling and ease of use.
In addition, the new ultrasound operates in the ideal MHz range for viewing all layers of the skin, which is essential for treating skin lesions. The SRT-100 Vision™ system’s built-in electronic medical record capability allows the operator to easily and accurately record and capture the ultrasound images to improve patient treatments.
“We are delighted to introduce our new SRT-100 Vision™ Solid State Ultrasound, offering increased productivity and higher resolution, and providing the best view of the epidermis in the market,” said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. “Upgraded SRT-100 Vision systems are available immediately.”
Monica DiGioia, Vice President of Clinical Affairs for Sensus Healthcare, commented, “No other ultrasound in the dermatology space has the capability of visualizing the epidermis. In addition, our new ergonomic probe employs single-use disposable standoffs on the tip of the ultrasound, which creates the ideal skin-to-probe distance while allowing for fast and quick setup and maintenance of the system. These changes significantly reduce cumbersome operations and setup times, while keeping patient safety firmly at the forefront.”
Sensus Healthcare notes customers with existing SRT-100 Vision™ systems are eligible for upgrades and should contact their sales representative.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world. For more information, visit www.sensushealthcare.com.
This press release includes statements that are, or may be deemed, ”forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from our international operations; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
LHA Investor Relations
Kim Sutton Golodetz